{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:26:54Z","timestamp":1790468814812,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.hoc.2020.02.007","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T20:12:07Z","timestamp":1586376727000},"page":"715-726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunomodulatory Agents in Follicular Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Loic","family":"Ysebaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2020.02.007_bib1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B-cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2020.02.007_bib2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/asheducation-2017.1.610","article-title":"Role of the microenvironment across histological subtypes of NHL","volume":"2017","author":"Tarte","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2020.02.007_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/MOH.0000000000000440","article-title":"Microenvironment signaling driving lymphomagenesis","volume":"25","author":"Verdiere","year":"2018","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.hoc.2020.02.007_bib4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrc.2017.127","article-title":"From genetics to the clinic: a translational perspective on follicular lymphoma","volume":"18","author":"Huet","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hoc.2020.02.007_bib5","doi-asserted-by":"crossref","unstructured":"Li X, Kositsky R, Anupama Reddy A, et\u00a0al. Whole exome and transcriptome sequencing in 1042 cases reveals distinct clinically relevant genetic subgroups of follicular lymphoma. American Society of Hematology meeting 2019, abstract #19. Orlando, December 7-10, 2019.","DOI":"10.1182\/blood-2019-130255"},{"key":"10.1016\/j.hoc.2020.02.007_bib6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2020.02.007_bib7","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/nm.3940","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2020.02.007_bib8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/2159-8290.CD-16-1417","article-title":"The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma","volume":"7","author":"Zhang","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2020.02.007_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activated mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2020.02.007_bib10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41571-019-0190-8","article-title":"Emerging epigenetic-modulating therapies in lymphoma","volume":"16","author":"Sermer","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.007_bib11","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1182\/blood-2012-12-473439","article-title":"A\u00a0transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis","volume":"123","author":"Berg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.007_bib12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2020.02.007_bib13","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2020.02.007_bib14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2020.02.007_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","article-title":"Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells","volume":"167","author":"Boice","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2020.02.007_bib16","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.02.007_bib17","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.007_bib18","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2012.44.2137","article-title":"Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation","volume":"31","author":"Kiaii","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.007_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.humpath.2017.03.023","article-title":"Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients","volume":"64","author":"Xerri","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.hoc.2020.02.007_bib20","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/blood-2011-04-345777","article-title":"Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study","volume":"118","author":"Laurent","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.007_bib21","doi-asserted-by":"crossref","unstructured":"Haebe S, Shree T, Sathe A, et\u00a0al. Site to site comparison of follicular lymphoma biopsies by single cell RNA sequencing. American Society of Hematology meeting 2019, abstract #297. Orlando, December 7-10, 2019.","DOI":"10.1182\/blood-2019-129445"},{"key":"10.1016\/j.hoc.2020.02.007_bib22","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood-2018-08-862292","article-title":"Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints","volume":"133","author":"Andor","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.007_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3324\/haematol.2016.150656","article-title":"The emerging role of immune checkpoint inhibition in malignant lymphoma","volume":"102","author":"Hude","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.02.007_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.007_bib25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.007_bib26","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4 : breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.hoc.2020.02.007_bib27","doi-asserted-by":"crossref","first-page":"e1026530","DOI":"10.1080\/2162402X.2015.1026530","article-title":"Several immune escape patterns in non-Hodgkin's lymphomas","volume":"4","author":"Laurent","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.hoc.2020.02.007_bib28","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.007_bib29","doi-asserted-by":"crossref","first-page":"e1409322","DOI":"10.1080\/2162402X.2017.1409322","article-title":"NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment","volume":"7","author":"Vo","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.hoc.2020.02.007_bib30","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.007_bib31","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2020.02.007_bib32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.15797","article-title":"Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma","volume":"185","author":"Chiu","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.02.007_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2018-10-879643","article-title":"Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy","volume":"134","author":"Zucca","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.007_bib34","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2020.02.007_bib35","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.02.007_bib36","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.007_bib37","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.007_bib38","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","article-title":"Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.02.007_bib39","doi-asserted-by":"crossref","unstructured":"Sharman J, Coleman M, Yacoub A, et\u00a0al. Interim analysis of phase IIIB MAGNIFY study of induction R2 followed by maintenance in patients with relapsed\/refractory indolent non-Hodgkin lymphoma. International Conference on Malignant Lymphoma 2019, abstract #70. Lugano, June 18-22, 2019 .","DOI":"10.1002\/hon.76_2629"},{"key":"10.1016\/j.hoc.2020.02.007_bib40","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.2217\/fon-2019-0193","article-title":"The role of obinutuzumab in the management of follicular lymphoma","volume":"15","author":"O'Nions","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.hoc.2020.02.007_bib41","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/13543784.2017.1373087","article-title":"Combination therapy with the type II anti-CD20 antibody obinutuzumab","volume":"26","author":"Klein","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.hoc.2020.02.007_bib42","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1038\/bcj.2013.32","article-title":"Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model","volume":"3","author":"Decaup","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2020.02.007_bib43","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.007_bib44","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41375-019-0559-9","article-title":"MRD response in relapsed\/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial","volume":"34","author":"Pott","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.02.007_bib45","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.02.007_bib46","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"supplement 1","key":"10.1016\/j.hoc.2020.02.007_bib47","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2018-99-112805","article-title":"A\u00a0phase II LYSA study of obinutuzumab combined with lenalidomide for advanced untreated follicular B-cell lymphoma in need of systemic therapy","volume":"132","author":"Morschhauser","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.007_bib48","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Ghosh N, Lossos I, et\u00a0al. Efficacy and safety of obinutuzumab\u00a0+ lenalidomide\u00a0+ atezolizumab in patients with relapsed or refractory follicular lymphoma: primary analysis of a phase 1b\/2 trial. International Conference on Malignant Lymphoma 2019, abstract #68. Lugano, June 18-22, 2019.","DOI":"10.1002\/hon.74_2629"},{"key":"10.1016\/j.hoc.2020.02.007_bib49","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.02.007_bib50","doi-asserted-by":"crossref","unstructured":"Advani R, Bartlett NL, Smith SM, et\u00a0al. The first-in-class anti-CD47 antibody HU5F9-G4+Rituximab induces durable responses in relapsed\/refractory DLBCL and indolent lymphoma: interim phase 1b\/2 results. International Conference on Malignant Lymphoma 2019, abstract #51. Lugano, June 18-22, 2019.","DOI":"10.1097\/01.HS9.0000561748.38640.dd"},{"issue":"10","key":"10.1016\/j.hoc.2020.02.007_bib51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-019-0246-0","article-title":"SIRP\u03b1 expression delineates subsets of intratumoral monocyte\/macrophages with different functional and prognostic impact in follicular lymphoma","volume":"9","author":"Chen","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2020.02.007_bib52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3324\/haematol.2014.113217","article-title":"Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia","volume":"100","author":"Fiorcari","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.02.007_bib53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.007_bib54","doi-asserted-by":"crossref","first-page":"e1054597","DOI":"10.1080\/2162402X.2015.1054597","article-title":"Functional expression of CD137 (4-1BB) on T helper follicular cells","volume":"4","author":"Alfaro","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.hoc.2020.02.007_bib55","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2020.02.007_bib56","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41467-019-10088-1","article-title":"Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with Fc\u03b3R affinity","volume":"10","author":"Qi","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2020.02.007_bib57","doi-asserted-by":"crossref","first-page":"e1115940","DOI":"10.1080\/2162402X.2015.1115940","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T\u00a0cells","volume":"5","author":"Ot\u00e1hal","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.hoc.2020.02.007_bib58","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hoc.2020.02.007_bib59","doi-asserted-by":"crossref","unstructured":"Budde LE, Sehn LH, Assouline S, et\u00a0al. Mosunetuzumab, a full-length bispecific CD20\/CD3 antibody, displays clinical activity in relapsed\/refractory B-cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study. American Society of Hematology meeting 2018, abstract #399, San Diego, December 1-4, 2018.","DOI":"10.1182\/blood-2018-99-118344"},{"key":"10.1016\/j.hoc.2020.02.007_bib60","doi-asserted-by":"crossref","unstructured":"Dickinson MJ, Morschhauser FM, Iacoboni G, et\u00a0al. CD20-TCB (RG6026), a novel \u201c2:1\u201d format T-cell engaging bispecific antibody, induces complete remissions in relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma. International Conference on Malignant Lymphoma 2019, abstract #53. Lugano, June 18-22, 2019.","DOI":"10.1002\/hon.59_2629"},{"key":"10.1016\/j.hoc.2020.02.007_bib61","unstructured":"Topp MS, Arnason J, Advani R, et\u00a0al. Anti-CD20 x anti-CD3 bispecific antibody in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma. International Conference on Malignant Lymphoma 2019, abstract #52. Lugano, June 18-22, 2019."},{"key":"10.1016\/j.hoc.2020.02.007_bib62","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2020.02.007_bib63","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/19420862.2018.1558698","article-title":"Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor\/CD19 association leading to impaired B-cell proliferation","volume":"11","author":"Hatterer","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.hoc.2020.02.007_bib64","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ymthe.2016.11.006","article-title":"Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies","volume":"25","author":"Dheilly","year":"2017","journal-title":"Mol Ther"},{"issue":"496","key":"10.1016\/j.hoc.2020.02.007_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5989","article-title":"Tumor-targeted 4-1BB agonists for combination with T\u00a0cell bispecific antibodies as off-the-shelf therapy","volume":"11","author":"Claus","year":"2019","journal-title":"Sci Transl Med"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:14:41Z","timestamp":1760184881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0889858820300320"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.02.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory Agents in Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}